Rallybio Quote - RLYB

Professional-Grade Tools, for Individual Investors.

Premium

Current Price

0.6589

Bid

0.6589

Ask

0.7022

Volume

0.00 Day's Range 0.00

0.6221 52 Week Range 3.46

Market Cap

27.336M

Previous Close

0.6589

Open

Last Trade

Last Trade Time

Financial Volume

VWAP

Average Volume (3m)

69,917

Shares Outstanding

41,487,586

Dividend Yield

PE Ratio

-0.37

Earnings Per Share (EPS)

-1.8

Revenue

Net Profit

-74.56M

Rallybio Corp is a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its lead program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening ... Rallybio Corp is a biopharmaceutical company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. Its lead program is for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns. Show more

Sector

Pharmaceutical Preparations

Industry

Pharmaceutical Preparations

Website

www.rallybio.com.

Headquarters

Wilmington, Delaware, USA

Founded

Rallybio Holdings LLC is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker RLYB. The last closing price for Rallybio was US$0.66. Over the last year, Rallybio shares have traded in a share price range of US$ 0.6221 to US$ 3.46.

Rallybio currently has 41,487,586 shares outstanding. The market capitalization of Rallybio is US$27.34 million. Rallybio has a price to earnings ratio (PE ratio) of -0.37.

Form 8-K - Current report

Rallybio to Present at the TD Cowen 45th Annual Health Care Conference

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for...

Form 4 - Statement of changes in beneficial ownership of securities

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Rallybio Announces Initiation of Dosing in RLYB212 Phase 2 Clinical Trial

– Key Data Readouts from Sentinel Participant Expected in 2Q 2025 and 3Q 2025 – Rallybio Corporation (Nasdaq: RLYB), a clinical-stage...

Rallybio Highlights 2024 Accomplishments and Anticipated Milestones for 2025

– Dosing of Sentinel (First) Participant in RLYB212 Phase 2 Clinical Trial Expected in 2Q 2025 – – Initiation of RLYB116 Confirmatory PK/PD Study...

Form 4 - Statement of changes in beneficial ownership of securities

Rallybio Announces Promising RLYB212 and RLYB332 Preclinical Data at the 66th American Society of Hematology Annual Meeting

Rallybio Corporation (Nasdaq: RLYB), a clinical-stage biotechnology company translating scientific advances into transformative therapies for...

Rallybio to Initiate RLYB116 Confirmatory Clinical PK/PD Study in Second Quarter 2025

-- New Biomarker Characterization Analyses Indicate RLYB116 Produced Complete and Sustained Complement Inhibition in Previous Phase 1 MAD Study –...

Rallybio Announces Publication of Target-Mediated Drug Disposition Modeling and Simulations Informing the RLYB212 Dosing Regimen in Pregnant Women

— Dosing Regimen to be Evaluated in Recently Initiated RLYB212 Phase 2 Clinical Trial — Rallybio Corporation (Nasdaq: RLYB), a clinical-stage...

Period	Change	Change %	Open	High	Low	Avg. Daily Vol	VWAP
1	-0.0302	-4.38252793499	0.6891	0.7494	0.6221	46312	0.6838114	CS
4	-0.0793	-10.7423462476	0.7382	0.8437	0.6221	54267	0.73019278	CS
12	-0.3311	-33.4444444444	0.99	1.0799	0.6221	69917	0.84796826	CS
26	-0.4411	-40.1	1.1	1.2401	0.6221	73776	0.9817745	CS
52	-1.0511	-61.4678362573	1.71	3.46	0.6221	465138	2.52291975	CS
156	-9.1811	-93.3038617886	9.84	15.89	0.6221	223897	3.51407715	CS
260	-14.2611	-95.5837801609	14.92	25.78	0.6221	201930	4.38978418	CS

RLYB - Frequently Asked Questions (FAQ)

What is the current Rallybio share price?

The current share price of Rallybio is US$ 0.6589

How many Rallybio shares are in issue?

Rallybio has 41,487,586 shares in issue

What is the market cap of Rallybio?

The market capitalisation of Rallybio is USD 27.34M

What is the 1 year trading range for Rallybio share price?

Rallybio has traded in the range of US$ 0.6221 to US$ 3.46 during the past year

What is the PE ratio of Rallybio?

The price to earnings ratio of Rallybio is -0.37

What is the reporting currency for Rallybio?

Rallybio reports financial results in USD

What is the latest annual profit for Rallybio?

The latest annual profit of Rallybio is USD -74.56M

What is the registered address of Rallybio?

The registered address for Rallybio is 251 LITTLE FALLS DRIVE, WILMINGTON, DELAWARE, 19808

What is the Rallybio website address?

The website address for Rallybio is www.rallybio.com.

Which industry sector does Rallybio operate in?

Rallybio operates in the PHARMACEUTICAL PREPARATIONS sector

Most Active
% Gainers
% Losers

Symbol	Price	Vol.
AAGRAfrican Agriculture Holdings Inc	US$ 0.1326 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	US$ 75.4153 (0.00%)	0
AADIAadi Bioscience Inc	US$ 1.98 (0.00%)	0
AACGATA Creativity Global	US$ 0.9899 (0.00%)	0
AACBUArtius II Acquisition Inc	US$ 10.10 (0.00%)	0
AAGRAfrican Agriculture Holdings Inc	US$ 0.1326 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	US$ 75.4153 (0.00%)	0
AADIAadi Bioscience Inc	US$ 1.98 (0.00%)	0
AACGATA Creativity Global	US$ 0.9899 (0.00%)	0
AACBUArtius II Acquisition Inc	US$ 10.10 (0.00%)	0
AAGRAfrican Agriculture Holdings Inc	US$ 0.1326 (0.00%)	0
AADRAdvisorShares Dorsey Wright ADR ETF	US$ 75.4153 (0.00%)	0
AADIAadi Bioscience Inc	US$ 1.98 (0.00%)	0
AACGATA Creativity Global	US$ 0.9899 (0.00%)	0
AACBUArtius II Acquisition Inc	US$ 10.10 (0.00%)	0